BioMarin Pharmaceutical Inc. To Host Second Quarter 2006 Earnings Call And Webcast On Wednesday, August 2 At 5:00 P.M. ET (23:00 CEST)
NOVATO, Calif., July 26 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, August 2, at 5:00 p.m. ET (23:00 CEST) to discuss second quarter 2006 financial results.
What: BioMarin Second Quarter 2006 Earnings Call and Webcast When: Wednesday, August 2, 2006 at 5:00 p.m. ET (23:00 CEST) U.S. / Canada Dial-in Number: 866.271.0675 International Dial-in Number: 617.213.8892 Participant Code: 93530506 Replay Dial-in Number: 888.286.8010 Replay International Dial-in Number: 617.801.6888 Replay Code: 52624487
Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for at least one week following the call.
About BioMarin
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio is comprised of two approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation. Investigational product candidates include Phenoptin(TM) (sapropterin dihydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU), and 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of poorly controlled hypertension. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.
Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.
BioMarin Pharmaceutical Inc.CONTACT: Investors: Joshua A. Grass, +1-415-506-6777, or Media: SusanFerris, +1-415-506-6701, both of BioMarin Pharmaceutical Inc.
Web site: http://www.BMRN.com//